Regencell Bioscience Holdings Limited Ordinary Shares
RGCRegencell Bioscience Holdings Limited is a biotechnology company focused on developing and commercializing traditional Chinese medicine-based products aimed at improving cognitive health and neurological conditions. The company leverages modern scientific approaches to enhance the efficacy of herbal formulations, targeting markets in Asia and globally.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| February 26, 2018 | $0.22 | 2018-02-15 | 2018-02-17 |
| December 15, 2017 | $0.22 | 2017-12-01 | 2017-12-04 |
| September 15, 2017 | $0.22 | 2017-08-31 | 2017-09-05 |
| June 15, 2017 | $0.22 | 2017-06-01 | 2017-06-05 |
| March 15, 2017 | $0.22 | 2017-03-01 | 2017-03-03 |
Dividends Summary
- Consistent Payer: Regencell Bioscience Holdings Limited Ordinary Shares has rewarded shareholders with 62 dividend payments over the past 14 years.
- Total Returned Value: Investors who held RGC shares during this period received a total of $23.76 per share in dividend income.
- Latest Payout: The most recent dividend of $0.22/share was paid 3064 days ago, on February 26, 2018.
- Yield & Schedule: RGC currently pays dividends quarterly with an annual yield of 17.53%.
- Dividend Growth: Since 2004, the dividend payout has grown by 22.2%, from $0.18 to $0.22.
- Dividend Reliability: RGC has maintained or increased its dividend for 13 consecutive payments.
Company News
Class action lawsuits have been filed against LKQ Corporation, Regencell Bioscience Holdings Limited, and Globant S.A. The complaints allege that defendants made materially false and misleading statements and failed to disclose material adverse facts about their businesses. LKQ faced issues with FinishMaster losing major customers post-acquisitio...
Rosen Law Firm has announced securities class action lawsuits against FS KKR Capital Corp. (FSK), Regencell Bioscience Holdings Limited (RGC), and Microsoft (MSFT). The FSK lawsuit alleges the company made false statements regarding portfolio restructuring effectiveness, investment valuations, and distribution strategy durability. Investors with ...
Rosen Law Firm is encouraging investors with losses exceeding $100,000 in Regencell Bioscience Holdings Limited, FS KKR Capital Corp., and Microsoft to join securities class action lawsuits. The firm has set a June 23, 2026 deadline for lead plaintiff claims. The lawsuits allege that defendants made false or misleading statements regarding market...
Faruqi & Faruqi, LLP is reminding investors in Regencell Bioscience Holdings Limited (RGC) of the June 23, 2026 deadline to seek lead plaintiff status in a federal securities class action. The lawsuit alleges that Regencell and its executives made false and misleading statements by concealing the company's vulnerability to market manipulation and...
Rosen Law Firm has issued multiple securities class action deadline alerts for investors. The primary case involves Sportradar Group AG (SRAD), where investors who purchased shares between November 7, 2024 and April 21, 2026 may be entitled to compensation. The lawsuit alleges that Sportradar made false statements about compliance and worked with...
